Trial reportBritish journal of haematology2018
Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.
Trial report in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Racial and socioeconomic differences in time to treatment initiation and outcomes in aggressive non-Hodgkin lymphoma.Blood neoplasia · 2026Article
- Article
- Diagnosis-to-Treatment Interval Reflects Clinical Urgency and Disease Burden in T-Lymphoblastic Lymphoma: A Multicenter Cohort Study.Journal of clinical medicine · 2026Article
- A rare and complex case report of superimposed clostridial spondylodiscitis and epidural abscess associated with spinal lymphoma of the thoracic spine.BMC infectious diseases · 2026Article
- Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.Annals of hematology · 2026Article
- Timing of multiple primary malignancies does not affect overall survival in lymphoma patients: a comparative study of 167 synchronous vs. metachronous cases.American journal of cancer research · 2026Article
- Opportunities and risks associated with external comparator cohorts in clinical drug development in hematology.Blood cancer journal · 2025Article
- Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B-Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts.Hematological oncology · 2025Review
- Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma.Cancer medicine · 2025Article
- Performance of Cross-Validated Targeted Maximum Likelihood Estimation.Statistics in medicine · 2025Article
- Implementing comprehensive geriatric assessment in an academic hematologic outpatient setting: experiences from medical doctors and patients.Frontiers in oncology · 2025Article
- Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis.Annals of hematology · 2024Article
- Non-linear relationship between soluble interleukin-2 receptor and prognosis of diffuse large B-cell lymphoma.Annals of hematology · 2024Observational
- Burkitt lymphoma manifested by initial oral and maxillofacial lesions: a case report in a child patient and review of related articles.Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2024Review
- Molecular Diagnostic Yield and Safety Profile of Ultrasound-Guided Lung Biopsies: A Cross-Sectional Study.Cancers · 2024Article
- RNA-seq analysis reveals candidate genes associated with proliferation, invasion, and migration in BCL11A knockdown B-NHL cell lines.Annals of hematology · 2023Article
- Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study.Journal of the American Geriatrics Society · 2023Article
- Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.Blood advances · 2023Article
- Synchronous multiple primary tumors in patients with malignant lymphoma: a retrospective study.BMC cancer · 2022Article
- Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.British journal of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In aggressive lymphomas, discrepancies in survival reported from experimental and observational studies may reflect selective non-enrolment of high-risk patients in trials. We examined the association between time from diagnosis to chemotherapy and overall survival in diffuse large B-cell (DLBCL), Burkitt (BL), mantle cell (MCL) and peripheral T-cell lymphoma (PTCL), using National Cancer Data Base records of 130 549 patients treated in 2004-2014. Across the histologies, patients who started chemotherapy within 7 days of diagnosis had more often high International Prognostic Index (IPI) or advanced-stage disease. The discrepancy in 3-year survival between groups treated within 7 or >30 days from diagnosis ranged from 14% in BL to 30% in MCL. After adjusting for the IPI, time to treatment was significantly associated with shorter overall survival. Using the group treated >30 days from diagnosis as reference, patients treated within 7 days had a hazard ratio of 1·38 [95% confidence interval (CI), 1·28-1·48] in DLBCL, 1·42 (95% CI, 1·22-1·66) in BL, 2·23 (95% CI, 1·79-2·78) in MCL and 1·46 (95% CI, 1·18-1·81) in PTCL. Time from diagnosis to treatment may reflect high-risk features uncaptured by standard prognostic assessments. Clinical trials should accommodate patients who need urgent therapy to improve external validity and detect treatment effects in high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.